Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis

Clinical Therapeutics

Volumn 31, Issue 3, 2009, Pages 580-584

  Caruso, Angelo ^a   Vecchio, Rosario ^a   Patti, Francesco ^a   Neri, Sergio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

cholestatic hepatitis; DRESS syndrome; eosinophilia; mitoxantrone; multiple sclerosis

Indexed keywords

BACLOFEN; BETA1A INTERFERON; METHYLPREDNISOLONE; MITOXANTRONE; PIRACETAM;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRESS SYNDROME; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MULTIPLE SCLEROSIS; PHYSICAL EXAMINATION; SKIN TEST;

ADMINISTRATION, ORAL; ADULT; BACLOFEN; BIOPSY; CHOLESTASIS; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS, TOXIC; HUMANS; HYPEREOSINOPHILIC SYNDROME; IMMUNOLOGIC FACTORS; INTRADERMAL TESTS; MITOXANTRONE; MULTIPLE SCLEROSIS; PIRACETAM;

EID: 64849101854     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.03.011     Document Type: Article

References (15)

1. Edwards I.R., and Aronson J.K. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 356 (2000) 1255-1259
2. Knowles S.R., Uerecht J., and Shear N.H. Idiosyncratic drug reactions: The reactive metabolite syndromes. Lancet 356 (2000) 1587-1591
3. Wolf R., Orion E., Marcos B., and Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 23 (2005) 171-181
4. In: Feldman M., Friedman L.S., Brandt L.J., and Sleisenger M.H. (Eds). Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 8th ed. (2006), Saunders, Philadelphia, Pa 1819
5. Bocquet H., Bagot M., and Roujeau J.C. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 15 (1996) 250-257
6. Wolf R., Matz H., Marcos B., and Orion E. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: The dilemma of classification. Clin Dermatol 23 (2005) 311-314
7. Roujeau J.C. Clinical heterogeneity of drug hypersensitivity. Toxicology 209 (2005) 123-129
8. Callot V., Roujeau J.C., Bagot M., et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol 132 (1996) 1315-1321
9. Dufour D.R., Lott J.A., Nolte F.S., et al. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 46 (2000) 2027-2049
10. Gruchalla R. Understanding drug allergies. J Allergy Clin Immunol 105 (2000) 5637-5644
11. Aberer W., Bircher A., Romano A., et al., for the Euopean Network for Drug Allergy (ENDA) and the EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: General considerations. Allergy 58 (2003) 854-863
12. Brockow K., Romno A., Blanca M., et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 57 (2002) 45-51
13. Lammintausta K., and Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 152 (2005) 968-974
14. Dávila González I., Sálazar Saez R., Moreno Rodilla E., et al. Hypersensitivity reactions to chemotherapy drugs. Alergol Inmunol Clin 15 (2000) 161-181
15. Dorr R.T., Alberts D.S., and Soble M. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Cancer Chemother Pharmacol 16 (1986) 91-94